Share This Author
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
COVID-19: combining antiviral and anti-inflammatory treatments
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response
- L. Castellano, G. Giamas, J. Stebbing
- BiologyProceedings of the National Academy of Sciences
- 15 September 2009
It is proposed that ERα, c-MYC, and miRNA transcriptional programs invoke a sophisticated network of interactions able to provide the wide range of coordinated cellular responses to estrogen.
Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts
The results demonstrate that cfDNA reflects persisting EpCAM-positive CTCs in patients with high CTC counts and therefore may enable monitoring of the metastatic burden for clinical decision-making.
A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI).
MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression.
Findings indicate that miRNAs act together to promote tumor progression; therapeutic strategies might require inhibition of several miRN as well as functional miRNA-mRNA interactions that contribute to growth of PDACs.
Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
In a case series of patients with bilateral COVID‐19 pneumonia, baricitinib treatment was associated with clinical and radiologic recovery, a rapid decline in SARS‐CoV‐2 viral load, inflammatory markers, and IL‐6 levels, and these data support further evaluation of the anti‐cytokine and anti‐viral activity of baricit inib and support its assessment in randomized trials in hospitalized CO VID‐19 patients.
Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer
- D. Pinato, R. Shiner, M. Seckl, J. Stebbing, R. Sharma, F. Mauri
- MedicineBritish Journal of Cancer
- 25 March 2014
An elevated NLR identifies operable NSCLC patients with a poor prognostic outlook and an OS difference of almost 2 years compared to those with a normal score at diagnosis, validates the clinical utility of the NLR in early-stage NSCLc.
Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
The functional importance of ER mutations in endocrine resistance, the utility of knock-in mutational models for investigating alternative therapeutic approaches and CDK7 inhibition as a potential therapy for endocrine-resistant breast cancer mediated by ER mutations are confirmed.